6
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Distribución espacial del seguimiento de cáncer de mama en un área rural de la estrategia de salud familiar Translated title: Distribuição espacial do rastreamento do câncer de mama em uma área rural da estratégia de saúde da familia Translated title: Spatial distribution of breast cancer tracking in a rural area of the family health strategy

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          RESUMEN: Objetivo: Demostrar mediante georreferenciación micro áreas con debilidades en el cribado del cáncer de mama en el área de Family Strategy Caxirimbu, área rural de Caxias, Maranhão, Brasil. Métodos: Investigación epidemiológica seccional. Se entrevistó a 211 mujeres, con edades entre 40 y 69 años, entre el 1 de abril y el 1 de septiembre de 2015. La técnica de georreferenciación se utilizó con la producción de coordenadas geográficas utilizando equipos GPS y la producción de mapas de distribución espacial. Resultados: En la distribución espacial, se encontró que el cribado del cáncer de mama en el área de Caxirimbu tiene un mayor alcance en las micro áreas en los márgenes de MA 034 y en las micro áreas cercanas a la unidad de salud. En esta cobertura, se encontró que de las 211 mujeres entrevistadas, 133 (63.0%) ya se habían sometido a una mamografía, estando cerca del parámetro indicado por el Ministerio de Salud, que es al menos el 70.0%. 42.0% (n = 56) ya se había sometido a una mamografía; 36.0% (n = 48), dos o tres mamografías, y el 22.0% (n = 29) informó haber realizado más de cuatro mamografías. El mapa mostró que 11 lugares de este examen son inaccesibles para las mujeres. En la distribución espacial, hubo una mayor distribución para la mamografía irregular, convergiendo con su frecuencia del 80.0%. Conclusión: La distribución espacial de los intervalos practicados por las mujeres para los exámenes de mamografía demostró la mayor parte de la ejecución y la ocurrencia de intervalos inadecuados, identificando la necesidad de implementar una detección organizada.

          Translated abstract

          RESUMO: Objetivo: Demonstrar por meio do georreferenciamento microáreas com fragilidades no rastreamento do câncer de mama em na área da estratégia de Família do Caxirimbu, zona rural de Caxias - Maranhão. Métodos: Pesquisa epidemiológica do tipo seccional. Foram pesquisadas 211 mulheres de 40 a 69 anos entre 01 de abril a 01 de setembro de 2015. Utilizou-se a técnica do georreferenciamento com produção de coordenadas geográficas por meio de equipamento GPS e produção de mapas de distribuição espacial. Resultados: Na distribuição espacial verificou-se que o rastreamento do câncer de mama na área de abrangência do Caxirimbu tem maior alcance nas microáreas as margens da MA 034 e em microáreas próxima a unidade de saúde. Nesta cobertura, verificou-se que das 211 mulheres entrevistadas, 133 (63,0%) já haviam realizado a mamografia ficando próximo do parâmetro indicado pelo ministério da saúde que é de no mínimo 70,0%. 42,0% (n=56) já haviam realizado 1 mamografia; 36,0% (n=48), 2 a 3 mamografias e; 22,0% (n=29) informou ter realizado mais de 4 mamografias. A execução da mamografia e sua regularidade teve uma frequência de 26,0% e 20,0%, respectivamente. O mapa mostrou que 11 localidades esse rastreamento está inacessível para as mulheres. Verificou-se na distribuição espacial maior distribuição para execução irregular da mamografia convergindo com sua frequência de 80,0%. Conclusão: A distribuição espacial dos intervalos praticados pelas mulheres para a realização dos exames de mamografia demonstrou que a maioria da execução e ocorrência de intervalos inadequados, identificando a necessidade de implementação de um rastreamento organizado.

          Translated abstract

          ABSTRACT: Objective: To demonstrate by means of georeferencing micro-areas with weaknesses in screening of breast cancer in the area of the Caxirimbu Family Strategy, rural zone of Caxias, Maranhão state, Brazil. Methods: Sectional epidemiological research. A total of 211 women aged 40 to 69 years were surveyed between April 1 and September 1, 2015. The georeferencing technique was used with the production of geographical coordinates using GPS equipment and the production of spatial distribution maps. Results: In the spatial distribution, it was found that breast cancer screening in the area covered by Caxirimbu has greater reach in the micro areas on the margins of MA 034 and in micro areas close to the health unit. In this coverage, it was found that of the 211 women interviewed, 133 (63.0%) had already undergone mammography, being close to the parameter indicated by the Ministry of Health, which is at least 70.0%. 42.0% (n= 56) had already undergone one mammogram; 36.0% (n= 48), two to three mammograms and; 22.0% (n= 29) reported having performed more than four mammograms. The map showed that 11 locations that tracking is inaccessible to women. In the spatial distribution, there was a greater distribution for irregular mammography performance, converging with its frequency of 80.0%. Conclusion: The spatial distribution of the intervals practiced by women for mammography exams demonstrated that most of the execution and occurrence of inadequate intervals, identifying the need to implement an organized screening.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: not found

          Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

          This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality). Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors. It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries. The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts. CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Screening for breast cancer: an update for the U.S. Preventive Services Task Force.

            This systematic review is an update of evidence since the 2002 U.S. Preventive Services Task Force recommendation on breast cancer screening. To determine the effectiveness of mammography screening in decreasing breast cancer mortality among average-risk women aged 40 to 49 years and 70 years or older, the effectiveness of clinical breast examination and breast self-examination, and the harms of screening. Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews (through the fourth quarter of 2008), MEDLINE (January 2001 to December 2008), reference lists, and Web of Science searches for published studies and Breast Cancer Surveillance Consortium for screening mammography data. Randomized, controlled trials with breast cancer mortality outcomes for screening effectiveness, and studies of various designs and multiple data sources for harms. Relevant data were abstracted, and study quality was rated by using established criteria. Mammography screening reduces breast cancer mortality by 15% for women aged 39 to 49 years (relative risk, 0.85 [95% credible interval, 0.75 to 0.96]; 8 trials). Data are lacking for women aged 70 years or older. Radiation exposure from mammography is low. Patient adverse experiences are common and transient and do not affect screening practices. Estimates of overdiagnosis vary from 1% to 10%. Younger women have more false-positive mammography results and additional imaging but fewer biopsies than older women. Trials of clinical breast examination are ongoing; trials for breast self-examination showed no reductions in mortality but increases in benign biopsy results. Studies of older women, digital mammography, and magnetic resonance imaging are lacking. Mammography screening reduces breast cancer mortality for women aged 39 to 69 years; data are insufficient for older women. False-positive mammography results and additional imaging are common. No benefit has been shown for clinical breast examination or breast self-examination.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              The benefits and harms of breast cancer screening: an independent review

              (2012)
              Whether breast cancer screening does more harm than good has been debated extensively. The main questions are how large the benefit of screening is in terms of reduced breast cancer mortality and how substantial the harm is in terms of overdiagnosis, which is defined as cancers detected at screening that would not have otherwise become clinically apparent in the woman's lifetime. An independent Panel was convened to reach conclusions about the benefits and harms of breast screening on the basis of a review of published work and oral and written evidence presented by experts in the subject. To provide estimates of the level of benefits and harms, the Panel relied mainly on findings from randomised trials of breast cancer screening that compared women invited to screening with controls not invited, but also reviewed evidence from observational studies. The Panel focused on the UK setting, where women aged 50-70 years are invited to screening every 3 years. In this Review, we provide a summary of the full report on the Panel's findings and conclusions. In a meta-analysis of 11 randomised trials, the relative risk of breast cancer mortality for women invited to screening compared with controls was 0·80 (95% CI 0·73-0·89), which is a relative risk reduction of 20%. The Panel considered the internal biases in the trials and whether these trials, which were done a long time ago, were still relevant; they concluded that 20% was still a reasonable estimate of the relative risk reduction. The more reliable and recent observational studies generally produced larger estimates of benefit, but these studies might be biased. The best estimates of overdiagnosis are from three trials in which women in the control group were not invited to be screened at the end of the active trial period. In a meta-analysis, estimates of the excess incidence were 11% (95% CI 9-12) when expressed as a proportion of cancers diagnosed in the invited group in the long term, and 19% (15-23) when expressed as a proportion of the cancers diagnosed during the active screening period. Results from observational studies support the occurrence of overdiagnosis, but estimates of its magnitude are unreliable. The Panel concludes that screening reduces breast cancer mortality but that some overdiagnosis occurs. Since the estimates provided are from studies with many limitations and whose relevance to present-day screening programmes can be questioned, they have substantial uncertainty and should be regarded only as an approximate guide. If these figures are used directly, for every 10,000 UK women aged 50 years invited to screening for the next 20 years, 43 deaths from breast cancer would be prevented and 129 cases of breast cancer, invasive and non-invasive, would be overdiagnosed; that is one breast cancer death prevented for about every three overdiagnosed cases identified and treated. Of the roughly 307,000 women aged 50-52 years who are invited to begin screening every year, just over 1% would have an overdiagnosed cancer in the next 20 years. Evidence from a focus group organised by Cancer Research UK and attended by some members of the Panel showed that many women feel that accepting the offer of breast screening is worthwhile, which agrees with the results of previous similar studies. Information should be made available in a transparent and objective way to women invited to screening so that they can make informed decisions. Copyright © 2012 Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Journal
                eg
                Enfermería Global
                Enferm. glob.
                Universidad de Murcia (Murcia, Murcia, Spain )
                1695-6141
                2020
                : 19
                : 60
                : 220-258
                Affiliations
                [1] Caxias Maranhão orgnameUniversidad Estatal de Maranhão Brasil
                [5] Caxias Maranhão orgnameUniversidad Estatal de Maranhão Brasil
                [2] Teresina Piauí orgnameUniversidade Federal do Piauí Brazil nataliamarinelli@ 123456ufpi.edu.br
                [6] Caxias Maranhão orgnameClínica Dr. Flávio Rocha Brasil
                [4] Teresina Piauí orgnameUniversidade Federal do Piauí Brazil
                [3] Teresina Piauí orgnameárea neurofuncional Brasil
                Article
                S1695-61412020000400220 S1695-6141(20)01906000220
                10.6018/eglobal.419551
                9dd5f92f-764a-4331-aafc-32c3d026bf9f

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 International License.

                History
                : 02 July 2020
                : 22 March 2020
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 19, Pages: 39
                Product

                SciELO Spain

                Categories
                Originales

                Mass Screening,Primary Health Care,Atención Primaria de Salud,Programas de Rastreamento,Breast Neoplasms,Tamizaje Masivo,Atenção Primária à Saúde,Neoplasias de la Mama,Câncer de mama

                Comments

                Comment on this article